Neuroimaging of vulnerability for recurrence in major depressive disorder. A prospective neuroimaging study investigating neurobiological and psychoneuro-endocrinological mechanisms underlying recurrent Major Depressive Disorder and predicting recurrence.

Neuroimaging of vulnerability for recurrence in major depressive disorder. A prospective neuroimaging study investigating neurobiological and psychoneuro-endocrinological mechanisms underlying recurrent Major Depressive Disorder and predicting recurrence. - DELTA-neuroimaging

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35896

Enrollment

100

Registered

2011-11-08

Start date

2012-12-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Remitted MDD-patients: - Age 35-65 yr - both sexes - *2 MDD episodes according to a structured interview for DSM-IV (SCID) - in stable remission defined as a Hamilton depression rating scale (HDRS) *7 and Inventory for depressive symptomatology (IDS-SR) *14 for at least 10 weeks.;Healthy controls: Controls will be matched with patients on age (±3 years), sex and estimated intelligence with the Dutch adult reading test (DART). - matched for age, sex and years of education - IDS-SR *14

Exclusion criteria

Exclusion criteria: Remitted MDD-patients: - current diagnosis of alcohol or drug dependence, psychotic or bipolar disorder, predominant anxiety disorder - standard fMRI exclusion criteria (claustrophobia, implanted metal objects in the bodies) - electroconvulsive therapy within two months before scanning - a history of head trauma or neurological disease, severe general physical illness ;Healthy controls: - Personal (assessed by SCID) or 1st degree relative with psychiatric disorder - current diagnosis of alcohol or drug dependence - standard fMRI exclusion criteria (claustrophobia, implanted metal objects in the bodies) - a history of head trauma or neurological disease, severe general physical illness

Design outcomes

Primary

Measure	Time frame
Measurements: Two phases (study entry and after recurrence of depressive symptoms) are studied. In Phase I, two blocks of psychological tests will be obtained, followed by structural and functional magnetic resonance imaging (MRI). During the scanning, a mood induction will be performed. In Phase II, when patients experience a recurrence during follow-up, we will invite them for a new psychological test and an MRI-scan. At approximately the same moment during follow-up we will invite a matched patient (matched by age ±10 years and sex) who has not experienced a recurrence by then, for repeated testing as well. Neuropsychological tests obtained are the Exogenous cueing task, Face recognition task, Emotional categorization task, Emotional Memory (both Phases) and the Dutch Adult Reading Test and the Negative affective priming (Phase I only). MRI scanning will consist of a structural scan, resting state scan, Reinforcement learning task, Magnetic resonance spectroscopy, Diffusion Tensor Imaging, Emotional faces and Internal Shift Task (both Phases); in Phase I an Emotion regulation task and a repeated resting-state scan after a sad mood induction will be made. Neurobiological/Neuroendocrine tests consist of blood collection for polyunsaturated fatty acids and brain derived neurotrophic factor, analysis of genetic polymorphisms and salivary cortisol measurements	—

Measure

Time frame

Measurements: Two phases (study entry and after recurrence of depressive symptoms) are studied. In Phase I, two blocks of psychological tests will be obtained, followed by structural and functional magnetic resonance imaging (MRI). During the scanning, a mood induction will be performed. In Phase II, when patients experience a recurrence during follow-up, we will invite them for a new psychological test and an MRI-scan. At approximately the same moment during follow-up we will invite a matched patient (matched by age ±10 years and sex) who has not experienced a recurrence by then, for repeated testing as well. Neuropsychological tests obtained are the Exogenous cueing task, Face recognition task, Emotional categorization task, Emotional Memory (both Phases) and the Dutch Adult Reading Test and the Negative affective priming (Phase I only). MRI scanning will consist of a structural scan, resting state scan, Reinforcement learning task, Magnetic resonance spectroscopy, Diffusion Tensor Imaging, Emotional faces and Internal Shift Task (both Phases); in Phase I an Emotion regulation task and a repeated resting-state scan after a sad mood induction will be made. Neurobiological/Neuroendocrine tests consist of blood collection for polyunsaturated fatty acids and brain derived neurotrophic factor, analysis of genetic polymorphisms and salivary cortisol measurements

—

Countries

Netherlands

Outcome results